Accelerate Diagnostics, Inc. (AXDX) Director Jack W. Schuler Buys 50,000 Shares of Stock

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Director Jack W. Schuler purchased 50,000 shares of Accelerate Diagnostics stock in a transaction dated Wednesday, November 8th. The shares were purchased at an average price of $18.46 per share, with a total value of $923,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Accelerate Diagnostics, Inc. (AXDX) opened at $19.15 on Tuesday. Accelerate Diagnostics, Inc. has a 1 year low of $16.75 and a 1 year high of $30.45.

TRADEMARK VIOLATION WARNING: “Accelerate Diagnostics, Inc. (AXDX) Director Jack W. Schuler Buys 50,000 Shares of Stock” was first published by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at https://www.truebluetribune.com/2017/11/14/accelerate-diagnostics-inc-axdx-director-jack-w-schuler-buys-50000-shares-of-stock.html.

A number of large investors have recently made changes to their positions in AXDX. American International Group Inc. grew its position in Accelerate Diagnostics by 7.1% in the first quarter. American International Group Inc. now owns 14,187 shares of the medical research company’s stock worth $343,000 after acquiring an additional 939 shares in the last quarter. FMR LLC purchased a new position in Accelerate Diagnostics in the first quarter worth $7,260,000. Teachers Advisors LLC grew its position in Accelerate Diagnostics by 2.9% in the first quarter. Teachers Advisors LLC now owns 39,105 shares of the medical research company’s stock worth $946,000 after acquiring an additional 1,087 shares in the last quarter. Legal & General Group Plc grew its position in Accelerate Diagnostics by 0.3% in the first quarter. Legal & General Group Plc now owns 5,123 shares of the medical research company’s stock worth $123,000 after acquiring an additional 15 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in Accelerate Diagnostics by 10.3% in the first quarter. Vanguard Group Inc. now owns 1,159,421 shares of the medical research company’s stock worth $28,058,000 after acquiring an additional 107,977 shares in the last quarter. Institutional investors own 44.44% of the company’s stock.

AXDX has been the subject of a number of recent analyst reports. BidaskClub lowered shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 9th. Zacks Investment Research lowered shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. Finally, ValuEngine lowered shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Three research analysts have rated the stock with a sell rating and two have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $33.00.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.

Insider Buying and Selling by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)

Receive News & Ratings for Accelerate Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply